Vorinostat and 177Lu-PSMA-617 for Prostate Cancer
Phase 2
15
about 3.3 years
All ages
Male only
1 site in WA
What this study is about
Researchers are testing how well vorinostat works in treating patients with prostate cancer that has spread to other parts of the body. This treatment involves a biopsy procedure, biospecimen collection, bone scan, computed tomography, fludeoxyglucose F-18, gallium Ga 68 gozetotide, lutetium Lu 177 vipivotide tetraxetan, positron emission tomography, and single photon emission computed tomography. The trial will last for about 1198 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Fludeoxyglucose F-18
- 2.Gallium Ga 68 Gozetotide
- 3.Take Lutetium Lu 177 Vipivotide Tetraxetan
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fludeoxyglucose (18F), gallium (68Ga) gozetotide, lutetium (177Lu) vipivotide tetraxetan, vorinostat
oral (Oral Capsule)
Secondary: Absolute change in PSMA standardized uptake value (SUV) mean, Incidence of adverse events, Objective radiographic response rate, Overall survival, PSA PFS, Progression free survival (PFS), Prostate specific antigen (PSA)50 response rate
biopsy, diagnostic, imaging
Oncology